Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Year After Chinese Health Authorities Vow To Rid Country Of Deliberately Adulterated Milk, A New Melamine Scandal Surfaces

This article was originally published in PharmAsia News

Executive Summary

BEIJING - One year after 11 Chinese ministries unveiled a massive program to ensure that the poison melamine was purged from national milk supplies, details are emerging of a new scandal involving the toxic chemical, along with a new government-aided cover-up in the rich coastal city of Shanghai

You may also be interested in...



Emerging Markets Earnings Roundup: Abbott Laboratories, Novartis (Part 1)

Abbott and Novartis talk at length in quarterly earning calls on emerging markets as key to the fortunes of both companies. China again dominated the subject, but chief executives at both firms say the rapid pace of change in the country’s health sector remains a singular opportunity that means the only option is to double down on efforts to overcome regulatory and other hurdles.

Emerging Markets Earnings Roundup: Abbott Laboratories, Novartis (Part 1)

Abbott and Novartis talk at length in quarterly earning calls on emerging markets as key to the fortunes of both companies. China again dominated the subject, but chief executives at both firms say the rapid pace of change in the country’s health sector remains a singular opportunity that means the only option is to double down on efforts to overcome regulatory and other hurdles.

China Drug Safety Remains Front and Center In Chromium Capsule Scandal

China’s latest product safety scandal could have far-reaching implications, potentially even disrupting China's tendering system for essential medicines.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC073206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel